Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-03-2022 | Positron Emission Tomography | Original Article

A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [¹⁸F]FDG PET/CT

Authors: Xiaohui Zhang, Lin Chen, Han Jiang, Xuexin He, Liu Feng, Miaoqi Ni, Mindi Ma, Jing Wang, Teng Zhang, Shuang Wu, Rui Zhou, Chentao Jin, Kai Zhang, Wenbin Qian, Zexin Chen, Cheng Zhuo, Hong Zhang, Mei Tian

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2022

Abstract

Purpose

This study aimed to develop a novel analytic approach based on 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) radiomic signature (RS) and International Prognostic Index (IPI) to predict the progression-free survival (PFS) and overall survival (OS) of patients with diffuse large B-cell lymphoma (DLBCL).

Methods

We retrospectively enrolled 152 DLBCL patients and divided them into a training cohort (n = 100) and a validation cohort (n = 52). A total of 1245 radiomic features were extracted from the total metabolic tumor volume (TMTV) and the metabolic bulk volume (MBV) of pre-treatment PET/CT images. The least absolute shrinkage and selection operator (LASSO) algorithm was applied to develop the RS. Cox regression analysis was used to construct hybrid nomograms based on different RS and clinical variables. The performances of hybrid nomograms were evaluated using the time-dependent receiver operator characteristic (ROC) curve and the Hosmer–Lemeshow test. The clinical utilities of prediction nomograms were determined via decision curve analysis. The predictive efficiency of different RS, clinical variables, and hybrid nomograms was compared.

Results

The RS and IPI were identified as independent predictors of PFS and OS, and were selected to construct hybrid nomograms. Both TMTV- and MBV-based hybrid nomograms had significantly higher values of area under the curve (AUC) than IPI in training and validation cohorts (all P < 0.05), while no significant difference was found between TMTV- and MBV-based hybrid nomograms (P > 0.05). The Hosmer–Lemeshow test showed that both TMTV- and MBV-based hybrid nomograms calibrated well in the training and validation cohorts (all P > 0.05). Decision curve analysis indicated that hybrid nomograms had higher net benefits than IPI.

Conclusion

The hybrid nomograms combining RS with IPI could significantly improve survival prediction in DLBCL. Radiomic analysis on MBV may serve as a potential approach for prognosis assessment in DLBCL.

Trial registration

NCT04317313. Registered March 16, 2020. Public site: https://clinicaltrials.gov/ct2/show/NCT04317313

Available only for authorised users

Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-25. https://doi.org/10.1093/annonc/mdv304.CrossRefPubMed

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. https://doi.org/10.1182/blood-2017-03-769620.CrossRefPubMedPubMedCentral

Shipp M. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94. https://doi.org/10.1056/NEJM199309303291402.CrossRef

Yim SK, Yhim HY, Han YH, Jeon SY, Lee NR, Song EK, et al. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and international prognostic index. Ann Hematol. 2019;98:2739–48. https://doi.org/10.1007/s00277-019-03834-4.CrossRefPubMed

Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev. 2018;32:400–15. https://doi.org/10.1016/j.blre.2018.03.005.CrossRefPubMed

Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021:in press. https://doi.org/10.1007/s00259-021-05234-1

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58. https://doi.org/10.1200/JCO.2013.53.5229.CrossRefPubMedPubMedCentral

Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502–8. https://doi.org/10.1007/s12185-011-0822-y.CrossRefPubMed

Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22. https://doi.org/10.1007/s00259-014-2822-7.CrossRefPubMed

10.

Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–202. https://doi.org/10.1002/cncr.27855.CrossRefPubMed

11.

Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R, et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019;46:1468–77. https://doi.org/10.1007/s00259-019-04313-8.CrossRefPubMed

12.

Kirienko M, Cozzi L, Antunovic L, Lozza L, Fogliata A, Voulaz E, et al. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. Eur J Nucl Med Mol Imaging. 2018;45:207–17. https://doi.org/10.1007/s00259-017-3837-7.CrossRefPubMed

13.

Mayerhoefer ME, Riedl CC, Kumar A, Gibbs P, Weber M, Tal I, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:2760–9. https://doi.org/10.1007/s00259-019-04420-6.CrossRefPubMedPubMedCentral

14.

Aide N, Fruchart C, Nganoa C, Gac AC, Lasnon C. Baseline ¹⁸F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol. 2020;30:4623–32. https://doi.org/10.1007/s00330-020-06815-8.

15.

Aide N, Talbot M, Fruchart C, Damaj G, Lasnon C. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:699–711. https://doi.org/10.1007/s00259-017-3899-6.CrossRefPubMed

16.

Dissaux G, Visvikis D, Da-Ano R, Pradier O, Chajon E, Barillot I, et al. Pretreatment ¹⁸F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med. 2020;61:814–20. https://doi.org/10.2967/jnumed.119.228106.

17.

Jiang Y, Yuan Q, Lv W, Xi S, Huang W, Sun Z, et al. Radiomic signature of ¹⁸F-fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits. Theranostics. 2018;8:5915–28. https://doi.org/10.7150/thno.28018.

18.

Peng H, Dong D, Fang MJ, Li L, Tang LL, Chen L, et al. Prognostic value of deep learning PET/CT-based radiomics: potential role for future individual induction chemotherapy in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2019;25:4271–9. https://doi.org/10.1158/1078-0432.CCR-18-3065.CrossRefPubMed

19.

Kirienko M, Sollini M, Corbetta M, Voulaz E, Gozzi N, Interlenghi M, et al. Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05371-7.CrossRefPubMedPubMedCentral

20.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. https://doi.org/10.1200/JCO.2013.54.8800.CrossRefPubMedPubMedCentral

21.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

22.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMed

23.

Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CAB, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–6. https://doi.org/10.1182/blood.V91.9.3340.CrossRefPubMed

24.

Delaby G, Hubaut MA, Morschhauser F, Besson A, Huglo D, Herbaux C, et al. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline ¹⁸F-FDG PET-CT. Leuk Lymphoma. 2020;61:1584–91. https://doi.org/10.1080/10428194.2020.1728750.

25.

Civelek A, Rana A, Malayeri A, Rodante J, Dey A, Jha A, et al. Intra and inter test reproducibility and comparison of PET-MRI and PET-CT derived ¹⁸F-FDG metric measurements. J Nucl Med. 2017;58:1343.

26.

van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7. https://doi.org/10.1158/0008-5472.CAN-17-0339.CrossRefPubMedPubMedCentral

27.

Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420. https://doi.org/10.1037//0033-2909.86.2.420.CrossRef

28.

Tibshirani R. The lasso method for variable selection in the cox model. Stat Med. 1997;16:385–95. https://doi.org/10.1002/(sici)1097-0258(19970228)16:4%3c385::aid-sim380%3e3.0.co;2-3.CrossRefPubMed

29.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70. https://doi.org/10.1200/JCO.2007.12.9791.CrossRefPubMed

30.

Ji GW, Zhang YD, Zhang H, Zhu FP, Wang K, Xia YX, et al. Biliary tract cancer at CT: a radiomics-based model to predict lymph node metastasis and survival outcomes. Radiology. 2019;290:90–8. https://doi.org/10.1148/radiol.2018181408.CrossRefPubMed

31.

Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44. https://doi.org/10.1111/j.0006-341x.2000.00337.x.CrossRefPubMed

32.

DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45. https://doi.org/10.2307/2531595.

33.

Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052–6. https://doi.org/10.1097/01.CCM.0000275267.64078.B0.CrossRefPubMed

34.

Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–74. https://doi.org/10.1177/0272989X06295361.CrossRefPubMedPubMedCentral

35.

Lue KH, Wu YF, Lin HH, Hsieh TC, Liu SH, Chan SC, et al. Prognostic value of baseline radiomic features of ¹⁸F-FDG PET in patients with diffuse large B-cell lymphoma. Diagnostics (Basel). 2020;11:36. https://doi.org/10.3390/diagnostics11010036.

36.

Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ. Radiomics of ¹⁸F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47:1168–82. https://doi.org/10.1007/s00259-019-04625-9.

37.

Zhang J, Zhao X, Zhao Y, Zhang J, Zhang Z, Wang J, et al. Value of pre-therapy ¹⁸F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1137–46. https://doi.org/10.1007/s00259-019-04592-1.

38.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90. https://doi.org/10.1038/s41591-018-0016-8.CrossRefPubMedPubMedCentral

39.

Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline ¹⁸F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46:1417–27. https://doi.org/10.1007/s00259-019-04309-4.

40.

Wei JH, Feng ZH, Cao Y, Zhao HW, Chen ZH, Liao B, et al. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Lancet Oncol. 2019;20:591–600. https://doi.org/10.1016/s1470-2045(18)30932-x.CrossRefPubMed

41.

Decazes P, Becker S, Toledano MN, Vera P, Desbordes P, Jardin F, et al. Tumor fragmentation estimated by volume surface ratio of tumors measured on ¹⁸F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:1672–9. https://doi.org/10.1007/s00259-018-4041-0.

42.

Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:680–8. https://doi.org/10.1007/s00259-017-3907-x.CrossRefPubMed

43.

Crandall JP, Fraum TJ, Lee M, Jiang L, Grigsby P, Wahl RL. Repeatability of ¹⁸F-FDG PET radiomic features in cervical cancer. J Nucl Med. 2021;62:707–15. https://doi.org/10.2967/jnumed.120.247999.

44.

van Velden FH, Kramer GM, Frings V, Nissen IA, Mulder ER, de Langen AJ, et al. Repeatability of radiomic features in non-small-cell lung cancer [¹⁸F]FDG-PET/CT studies: impact of reconstruction and delineation. Mol Imaging Biol. 2016;18:788–95. https://doi.org/10.1007/s11307-016-0940-2.

45.

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62. https://doi.org/10.1038/nrclinonc.2017.141.CrossRefPubMed

46.

Blanc-Durand P, Jegou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodere F, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2021;48:1362–70. https://doi.org/10.1007/s00259-020-05080-7.CrossRefPubMed

Title: A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT
Authors: Xiaohui Zhang
Lin Chen
Han Jiang
Xuexin He
Liu Feng
Miaoqi Ni
Mindi Ma
Jing Wang
Teng Zhang
Shuang Wu
Rui Zhou
Chentao Jin
Kai Zhang
Wenbin Qian
Zexin Chen
Cheng Zhuo
Hong Zhang
Mei Tian
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: Positron Emission Tomography
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05572-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [¹⁸F]FDG PET/CT

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 4/2022

Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy

Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment

Comments on “Patients’ findings after COVID-19 infection and vaccinations: what to expect from [18F]FDG PET/CT”